Even though KRAS and BRAF act in the same pathway, as evidenced by the mutual exclusivity of somatic mutations in CRC, different clinico-pathological phenotypes have been ascribed to different KRAS and BRAF mutations. Here, KRAS is linked to colorectal carcinoma.